EHA2021 abstracts: What’s hot in and AL amyloidosis?

To help navigate the exciting content being presented at the EHA2021 Virtual Congress, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in multiple myeloma and amyloid light-chain (AL) amyloidosis.

Click the abstracts to view Newly diagnosed multiple myeloma

DARATUMUMAB MAINTENANCE VS OBSERVATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA S180 TREATED WITH , THALIDOMIDE, AND Philippe Moreau ± AND ASCT: CASSIOPEIA PART 2 RESULTS

UPDATED INTERIM ANALYSIS OF THE GMMG-CONCEPT TRIAL INVESTIGATING , , S183 , AND DEXAMETHASONE (ISA-KRD) IN Katja Weisel FRONT-LINE TREATMENT OF HIGH-RISK MULTIPLE MYELOMA

MEASURABLE RESIDUAL DISEASE (MRD) EVALUATION DURING IXAZOMIB (IXA) MAINTENANCE IN NEWLY S184 DIAGNOSED MULTIPLE MYELOMA (NDMM): A LARGE Bruno Paiva ANALYSIS OF 1280 PATIENTS (PTS) ENROLLED IN TOURMALINE-MM3 AND -MM4

ANALYSIS OF A PHASE 2 MINIMAL RESIDUAL DISEASE (MRD)-ADAPTIVE TRIAL OF ELOTUZUMAB, CARFILZOMIB, EP1010 Benjamin A Derman LENALIDOMIDE, AND DEXAMETHASONE (ELO-KRD) FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)

ASSESSMENT OF TREATMENT RESPONSE BY MASS SPECTROMETRY IN NEWLY DIAGNOSED MULTIPLE EP1012 Noemi Puig MYELOMA PATIENTS FROM THE GEM2012MENOS65 : COMPARISON WITH STANDARD SPEP/IFE

OVERALL SURVIVAL RESULTS WITH DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LB1901 LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT- Thierry Facon INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 3 MAIA STUDY

CIRCULATING TUMOR CELLS (CTC) ARE THE MOST S185 RELEVANT DIAGNOSTIC BIOMARKER IN TRANSPLANT- Juan-José Garcés ELIGIBLE MULTIPLE MYELOMA (MM) Relapsed/refractory multiple myeloma

UPDATES FROM ICARIA-MM, A PHASE 3 STUDY OF ISATUXIMAB (ISA) PLUS AND LOW-DOSE S186 Aurore Perrot DEXAMETHASONE (PD) VERSUS PD IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

ONCE WEEKLY SELINEXOR, CARFILZOMIB, AND S188 DEXAMETHASONE (XKD) IN CARFILZOMIB Cristina Gasparetto NONREFRACTORY MULTIPLE MYELOMA (MM) PATIENTS

UPDATED CARTITUDE-1 RESULTS OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED EP964 Saad Usmani CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EFFICACY AND SAFETY OF THE BCMA-DIRECTED CAR-T CELL THERAPY, CILTACABTAGENE AUTOLEUCEL, IN PATIENTS S190 WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1–3 Mounzer Agha PRIOR LINES OF THERAPY: INITIAL RESULTS FROM CARTITUDE-2

TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) × CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH S193 Niels WCJ van de Donk RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1 RESULTS

MAGNETISMM-1: PHASE 1 STUDY OF ELRANATAMAB (PF- 06863135), A B-CELL MATURATION ANTIGEN (BCMA) S192 TARGETED CD3-ENGAGING BISPECIFIC ANTIBODY, FOR Caitlin Costello PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM) ISB 1342: A FIRST-IN-CLASS CD38 T CELL ENGAGER FOR THE EP938 TREATMENT OF RELAPSED REFRACTORY MULTIPLE Mario Perro MYELOMA IBERDOMIDE (IBER) IN COMBINATION WITH DEXAMETHASONE (DEX) AND DARATUMUMAB (DARA), S187 BORTEZOMIB (BORT), OR CARFILZOMIB (CFZ) IN PATIENTS Sagar Lonial (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

A PROSPECTIVE, NON-INTERVENTIONAL, MULTINATIONAL STUDY OF REAL-LIFE STANDARD OF CARE IN PATIENTS EP987 WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH Maria-Victoria Mateos ≥3 PRIOR LINES OF THERAPY: INTERIM DATA FROM LOCOMMOTION AL amyloidosis

UPDATED RESULTS FROM PHASE 3 ANDROMEDA STUDY OF PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN S189 AMYLOIDOSIS TREATED WITH BORTEZOMIB, Efstathios Kastritis CYCLOPHOSPHAMIDE, AND DEXAMETHASONE PLUS SUBCUTANEOUS DARATUMUMAB Follow us on Twitter to keep up to date with the latest from the EHA2021 Virtual Congress!

@MM_Hub #EHA2021 multiplemyelomahub.com